- Home
- CYN vs CALC Comparison
CYN vs CALC Comparison
Compare CYN & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYN
- CALC
- Stock Information
- Founded
- CYN 2013
- CALC 2011
- Country
- CYN United States
- CALC United States
- Employees
- CYN N/A
- CALC N/A
- Industry
- CYN EDP Services
- CALC Biotechnology: Pharmaceutical Preparations
- Sector
- CYN Technology
- CALC Health Care
- Exchange
- CYN Nasdaq
- CALC Nasdaq
- Market Cap
- CYN 28.0M
- CALC 22.9M
- IPO Year
- CYN 2021
- CALC N/A
- Fundamental
- Price
- CYN $10.48
- CALC $1.61
- Analyst Decision
- CYN
- CALC Strong Buy
- Analyst Count
- CYN 0
- CALC 3
- Target Price
- CYN N/A
- CALC $16.33
- AVG Volume (30 Days)
- CYN 12.2M
- CALC 28.9K
- Earning Date
- CYN 08-06-2025
- CALC 08-11-2025
- Dividend Yield
- CYN N/A
- CALC N/A
- EPS Growth
- CYN N/A
- CALC N/A
- EPS
- CYN N/A
- CALC N/A
- Revenue
- CYN $409,777.00
- CALC N/A
- Revenue This Year
- CYN $1,162.03
- CALC N/A
- Revenue Next Year
- CYN $427.83
- CALC N/A
- P/E Ratio
- CYN N/A
- CALC N/A
- Revenue Growth
- CYN N/A
- CALC N/A
- 52 Week Low
- CYN $3.62
- CALC $1.42
- 52 Week High
- CYN $1,600.50
- CALC $5.97
- Technical
- Relative Strength Index (RSI)
- CYN 58.36
- CALC 49.89
- Support Level
- CYN $12.20
- CALC $1.59
- Resistance Level
- CYN $17.20
- CALC $1.69
- Average True Range (ATR)
- CYN 3.78
- CALC 0.15
- MACD
- CYN 0.27
- CALC 0.01
- Stochastic Oscillator
- CYN 18.39
- CALC 52.26
About CYN Cyngn Inc.
Cyngn Inc is an industrial autonomous vehicle technology company. Its flagship innovation is DriveMod, an autonomous driving solution that can be flexibly deployed on multiple vehicle types manufactured by Original Equipment Manufacturers in various environments.
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.